Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor modelsShigemi Fukami(Novartis (Japan)), Shinji Hatakeyama(Novartis (Switzerland))BMC Research NotesJune 18, 201910.1186/s13104-019-4389-7Cited by 15SaveCiteExport RISWatch citationsRelated PapersAnalyses of Group III Secreted Phospholipase A2 Transgenic Mice Reveal Potential Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, and Atherosclerosis|Journal of Biological Chemistry|2008|131